SLGL — Sol-Gel Technologies Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1684693 ·
Israel
Last close
$70.34
Market Cap
$230.29M
52W High
$97.97
52W Low
$28.81
ADV30
56,162
Next earnings
2026-11-19
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 591,000 | — | -4,162,000 | -3,681,000 | 53,756,000 | 16,662,000 | 5,660,000 |
| Mar 2026 | 108,000 | — | -3,855,000 | -3,727,000 | 58,550,000 | 10,136,000 | 7,144,000 |
| Dec 2025 | 696,000 | — | -3,411,000 | -2,987,000 | 29,917,000 | 11,033,000 | 7,106,000 |
| Sep 2025 | 400,000 | — | -6,288,000 | -5,942,000 | 34,592,000 | 6,705,000 | 8,562,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-240,737,000
Inventory
—
Receivables
$1,067,000
ST Investments
$42,692,000
EBIT TTM
$-2,324,000
Pretax Income TTM
$-1,046,000
Interest Exp TTM
—
Analysts
3
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,795,000
EBITDA
$-17,690,000
Free Cash Flow
$-2,120,250
Enterprise Value
$168,728,496
Total Cash
$47,929,000
Total Debt
$770,000
Shares Out
3,273,999
Trailing EPS
$-5.62
Book Value
$14.69
ROE
-40.9%
ROA
-23.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 19,388,000 | -7,538,000 | -6,127,000 | 29,917,000 | 7,106,000 | 22,811,000 | 322,000 |
| Dec 2024 | 11,538,000 | -12,014,000 | -10,580,000 | 35,846,000 | 6,996,000 | 28,850,000 | -13,889,000 |
| Dec 2023 | 1,554,000 | -29,305,000 | -27,238,000 | 45,287,000 | 6,643,000 | 38,644,000 | -17,730,000 |
| Dec 2022 | 3,883,000 | -16,244,000 | -14,923,000 | 46,628,000 | 4,415,000 | 42,213,000 | -9,484,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-7.70
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| KROS | Keros Therapeutics, Inc. | $230.79M | $11.64 | — |
| CAMP | Camp4 Therapeutics Corp | $232.19M | $3.70 | — |
| EVMN | Evommune, Inc. | $232.63M | $6.41 | — |
| MGNX | MACROGENICS INC | $226.14M | $3.55 | — |
| AKBA | Akebia Therapeutics, Inc. | $225.79M | $0.81 | — |
News headlines (Yahoo Finance, 1h cache)
Sol-Gel Technologies to Host KOL Investor Day for SGT-610 on October 14, 2026
2026-09-30 13:14 · Yahoo
Sol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin Syndrome
2026-09-17 12:30 · Yahoo
Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
2026-08-20 12:30 · Yahoo
SolGel Technologies (SLGL) Upgraded to Buy: Here's Why
2026-10-08 15:00 · Yahoo
SolGel Technologies (SLGL) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-09-17 13:55 · Yahoo
Bausch Health (BHC) Q2 Earnings and Revenues Beat Estimates
2026-07-30 00:35 · Yahoo
Sol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate Updates
2026-05-28 12:00 · Yahoo
Metagenomi Therapeutics (MGX) Reports Q2 Loss, Lags Revenue Estimates
2026-08-10 21:55 · Yahoo
Sol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten Offering
2026-03-24 01:38 · Yahoo
Sol-Gel Technologies Ltd. (SLGL) Reports Q4 Loss, Misses Revenue Estimates
2026-03-19 18:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.